

Patients' perceptions about genomics profiling and immunotherapy

Cris Decat Bergerot, PhD
Postdoctoral Fellow
Department of Medical Oncology & Therapeutic Science
City of Hope Comprehensive Cancer Center

International Genitourinary Oncology Congress




No disclosure.

International Genitourinary Oncology Congress



My Brief Background



Patients' Perception Studies

Genomic Profiling

GOAL

To assess patients' knowledge, attitudes, and expectations of patients diagnosed with metastatic GU cancer regarding the Genomic Profiling

MEASURES

Survey: previous experience, beliefs, expectations and concerns regarding genomic testing

PROMIS Anxiety

PROMIS Depression

Functional Assessment of Cancer Therapy General (FACT-G)

Immunotherapy

GOAL

To assess patient's perception of immunotherapy at two time points

MEASURES

Survey: general knowledge, beliefs, expectations and concerns regarding immunotherapy

PROMIS Anxiety

PROMIS Depression

Functional Assessment of Cancer Therapy General (FACT-G)

Patients' Perceptions - Genomic Profiling (N=16)

PRESENT SITUATION

Control the disease (56%)
Fully active (62%)

GENOMIC PROFILING

HOPE (100%)

Treatment options (75%)
Better outcome (50%)
Chances of being cured (44%)

KNOWLEDGE

Before: searched online (25%)
After: understand well informations (81%)

BENEFITS

Learn about their genes (81%)
Learn about family genes (62%)

TOP REASONS

#1 Guide course of treatment
#2 Predict outcome
#3 Reduce unnecessary treatment

WORRIES

Feel anxious (25%)
Less treatable/more aggressive (37%)

Patients' Perceptions - Immunotherapy (N=7)

PRESENT SITUATION


Control the disease (86%)
Fully active (71%)

TOP BENEFITS

#1 Efficacy
#2 Mechanism of action
#3 Side effects/tolerability

TOP BARRIERS

#1 Cost
#2 Lack of knowledge
#3 Efficacy data



IMMUNOTHERAPY

BELIEFS

Innovative option (100%)
Fewer side effects (100%)
Easier to administer (43%)
Effect: few weeks/months (43%)

EXPECTATION

Keep pace w the tumor (86%)
Increase survival (86%)
Control the cancer (71%)
Prevent other cancers (43%)

INCREASE KNOWLEDGE

#1 Physical education
#2 Class information
#3 Clinical trial data

In Summary...

- Patients are motivated with genomic profiling and immunotherapy
- Moderate general level of knowledge and understanding
- Further strategies (education and counseling programs) to better translate these advances
 - To support, decrease anxiety and improve clinical decision making

2018 Genitourinary Cancers Symposium

TRANSLATING EVIDENCE TO MULTIDISCIPLINARY CARE

February 8-10, 2018 | Moscone West Building | San Francisco, CA | #GU18

Abstract Submission ID:
206657

Abstract Number: 471

Abstract Title: *Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC).*

Presentation Information:
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile,

Dear Dr. Bergerot,

Thank you for submitting your abstract 206657: *Association of somatic mutational burden with depression and anxiety in patients with metastatic urothelial cancer (mUC)*, to the 2018 Genitourinary Cancers Symposium. This year, we received more than 750 abstract submissions, which were reviewed by the Symposium Program Committee. **I am pleased to inform you that your abstract has been accepted for poster presentation.**

Please accept or decline this invitation to present your abstract using the "Confirm Your Participation" link below by December 8, 2017. Our [Speaker Center Website](#) also provides access to view session details, including session date, time, and location, presentation guidelines, and registration information.

2018 Genitourinary Cancers Symposium

TRANSLATING EVIDENCE TO MULTIDISCIPLINARY CARE

February 8-10, 2018 | Moscone West Building | San Francisco, CA | #GU18

Abstract Submission ID:
206755

Abstract Number: 649

Abstract Title: *Correlation between depression/anxiety and somatic circulating tumor DNA (ctDNA) alterations in patients with metastatic renal cell carcinoma (mRCC).*

Presentation Information:
Poster Session C: Renal

Dear Dr. Bergerot,

Thank you for submitting your abstract 206755: *Correlation between depression/anxiety and somatic circulating tumor DNA (ctDNA) alterations in patients with metastatic renal cell carcinoma (mRCC)*, to the 2018 Genitourinary Cancers Symposium. This year, we received more than 750 abstract submissions, which were reviewed by the Symposium Program Committee. **I am pleased to inform you that your abstract has been accepted for poster presentation.**

Please accept or decline this invitation to present your abstract using the "Confirm Your Participation" link below by December 8, 2017. Our [Speaker Center Website](#) also provides access to view session details, including session date, time, and location, presentation guidelines, and registration information.



Thank You!

International Genitourinary Oncology Congress

